Alkermes Plc (ALKS) - Total Assets
Based on the latest financial reports, Alkermes Plc (ALKS) holds total assets worth $4.39 Billion USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Alkermes Plc - Total Assets Trend (1991–2025)
This chart illustrates how Alkermes Plc's total assets have evolved over time, based on quarterly financial data. Also see Alkermes Plc (ALKS) market capitalisation for the company's overall valuation and market capitalisation.
Alkermes Plc - Asset Composition Analysis
Current Asset Composition (December 2025)
Alkermes Plc's total assets of $4.39 Billion consist of 76.2% current assets and 23.8% non-current assets. Review ALKS total debt and obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 44.3% |
| Accounts Receivable | $334.02 Million | 13.2% |
| Inventory | $196.62 Million | 7.8% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $83.84 Million | 3.3% |
| Goodwill | $83.84 Million | 3.3% |
Asset Composition Trend (1991–2025)
This chart illustrates how Alkermes Plc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See ALKS stock price and chart for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Alkermes Plc's current assets represent 76.2% of total assets in 2025, a decrease from 83.3% in 1991.
- Cash Position: Cash and equivalents constituted 44.3% of total assets in 2025, up from 5.6% in 1991.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, an increase from 0.0% in 1991.
- Asset Diversification: The largest asset category is accounts receivable at 13.2% of total assets.
Alkermes Plc Competitors by Total Assets
Key competitors of Alkermes Plc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Beijing Tongrentang Co Ltd
SHG:600085
|
China | CN¥29.95 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥13.98 Billion |
|
Shenzhen Kangtai Biological Products Co Ltd
SHE:300601
|
China | CN¥13.93 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
|
Sun Pharma Advanced Research Company Limited
NSE:SPARC
|
India | Rs3.22 Billion |
|
ChengDa Pharmaceuticals Co. Ltd.
SHE:301201
|
China | CN¥2.35 Billion |
Alkermes Plc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.30 | 3.23 | 2.32 |
| Quick Ratio | 1.85 | 2.85 | 2.02 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $860.82 Million | $1.13 Billion | $600.02 Million |
Alkermes Plc - Advanced Valuation Insights
This section examines the relationship between Alkermes Plc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.28 |
| Latest Market Cap to Assets Ratio | 2.71 |
| Asset Growth Rate (YoY) | 23.1% |
| Total Assets | $2.53 Billion |
| Market Capitalization | $6.85 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Alkermes Plc's assets at a significant premium (2.71x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Alkermes Plc's assets grew by 23.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Alkermes Plc (1991–2025)
The table below shows the annual total assets of Alkermes Plc from 1991 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $2.53 Billion | +23.09% |
| 2024-12-31 | $2.06 Billion | -3.78% |
| 2023-12-31 | $2.14 Billion | +8.77% |
| 2022-12-31 | $1.96 Billion | -2.99% |
| 2021-12-31 | $2.02 Billion | +3.83% |
| 2020-12-31 | $1.95 Billion | +7.99% |
| 2019-12-31 | $1.81 Billion | -1.07% |
| 2018-12-31 | $1.83 Billion | +1.55% |
| 2017-12-31 | $1.80 Billion | +4.10% |
| 2016-12-31 | $1.73 Billion | -6.97% |
| 2015-12-31 | $1.86 Billion | -3.41% |
| 2014-12-31 | $1.92 Billion | +21.78% |
| 2013-12-31 | $1.58 Billion | +7.30% |
| 2012-12-31 | $1.47 Billion | +2.44% |
| 2011-12-31 | $1.44 Billion | +217.21% |
| 2010-12-31 | $452.45 Million | -12.25% |
| 2009-12-31 | $515.60 Million | -0.83% |
| 2008-12-31 | $519.90 Million | -20.78% |
| 2007-12-31 | $656.31 Million | -10.15% |
| 2006-12-31 | $730.48 Million | +29.66% |
| 2005-12-31 | $563.38 Million | +66.25% |
| 2004-12-31 | $338.87 Million | +67.92% |
| 2003-12-31 | $201.81 Million | -31.97% |
| 2002-12-31 | $296.67 Million | +1.90% |
| 2001-12-31 | $291.14 Million | -24.64% |
| 2000-12-31 | $386.32 Million | -4.29% |
| 1999-12-31 | $403.62 Million | +89.45% |
| 1998-12-31 | $213.04 Million | -3.39% |
| 1997-12-31 | $220.52 Million | +110.63% |
| 1996-12-31 | $104.70 Million | +81.73% |
| 1995-12-31 | $57.61 Million | +56.98% |
| 1994-12-31 | $36.70 Million | -20.73% |
| 1993-12-31 | $46.30 Million | -14.26% |
| 1992-12-31 | $54.00 Million | -3.05% |
| 1991-12-31 | $55.70 Million | -- |
About Alkermes Plc
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and … Read more